- HIFI Study is the largest (N = 3,328) prospective, comparative, multi-center clinical study ever conducted comparing prostate cancer treatments
- Positive study results are expected to drive further adoption of Focal One as a first line treatment option for the management of localized prostate cancer
- Study shows Focal One Robotic HIFU is non-inferior to surgery, meeting primary endpoint of non-inferiority for Salvage Treatment-free Survival (STFS) after High Intensity Focused Ultrasounds (HIFU) compared to Radical Prostatectomy (RP) at 30 months
- Study shows that patients receiving HIFU had better outcomes with respect to urinary continence and erectile function compared to patients receiving RP
EDAP TMS Publishes HIFI Study Results In European Urology
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.